Imaging genetics: implications for research on variable antidepressant drug response

Genetic variation of SLC6A4, HTR1A, MAOA, COMT and BDNF has been associated with depression, variable antidepressant drug responses as well as impacts on brain regions of emotion processing that are modulated by antidepressants. Pharmacogenetic studies are using psychometric outcome measures of drug response and are hampered by small effect sizes that might be overcome by the use of intermediate endophenotypes of drug response, which are suggested by imaging studies. Such an approach will not only tighten the relationship between genes and drug response, but also yield new insights into the neurobiology of depression and individual drug responses. This article provides a comprehensive overview of pharmacogenetic, imaging genetics and drug response studies, utilizing imaging techniques within the context of antidepressive drug therapy.

[1]  Dan J Stein,et al.  Brain-Derived Neurotrophic Factor: The Neurotrophin Hypothesis of Psychopathology , 2008, CNS Spectrums.

[2]  J. Groves,et al.  Is it time to reassess the BDNF hypothesis of depression? , 2007, Molecular Psychiatry.

[3]  Jeffrey H Meyer,et al.  Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. , 2007, Journal of psychiatry & neuroscience : JPN.

[4]  Kiyotaka Nemoto,et al.  Dose-dependent effect of the Val66Met polymorphism of the brain-derived neurotrophic factor gene on memory-related hippocampal activity , 2008, Neuroscience Research.

[5]  R Todd Ogden,et al.  Higher 5-HT1A Receptor Binding Potential During a Major Depressive Episode Predicts Poor Treatment Response: Preliminary Data from a Naturalistic Study , 2006, Neuropsychopharmacology.

[6]  Leanne M Williams,et al.  Brain derived neurotrophic factor Val66Met polymorphism, the five factor model of personality and hippocampal volume: Implications for depressive illness , 2009, Human brain mapping.

[7]  B. Gutiérrez,et al.  Evidence for a combined genetic effect of the 5-HT1A receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram , 2005, Journal of psychopharmacology.

[8]  John Suckling,et al.  Brain Imaging Correlates of Depressive Symptom Severity and Predictors of Symptom Improvement After Antidepressant Treatment , 2007, Biological Psychiatry.

[9]  Dan J Stein Depression, Anhedonia, and Psychomotor Symptoms: The Role of Dopaminergic Neurocircuitry , 2008, CNS Spectrums.

[10]  M. Barrot,et al.  Essential role of brain-derived neurotrophic factor in adult hippocampal function. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R Kohnen,et al.  The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression , 2005, The Pharmacogenomics Journal.

[12]  Marcus R. Munafò,et al.  Serotonin Transporter (5-HTTLPR) Genotype and Amygdala Activation: A Meta-Analysis , 2008, Biological Psychiatry.

[13]  G. Glover,et al.  A Genetic Variant BDNF Polymorphism Alters Extinction Learning in Both Mouse and Human , 2010, Science.

[14]  Marc Laruelle,et al.  Central serotonin transporter availability measured with [123I]beta-CIT SPECT in relation to serotonin transporter genotype. , 2004, The American journal of psychiatry.

[15]  R A Bryant,et al.  Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety , 2009, Molecular Psychiatry.

[16]  A. Seeringer,et al.  Pharmacogenetics-guided dose modifications of antidepressants. , 2008, Clinics in laboratory medicine.

[17]  I. Kirsch,et al.  Efficacy of antidepressants in adults , 2005, BMJ : British Medical Journal.

[18]  John D E Gabrieli,et al.  Amygdala reactivity to emotional faces predicts improvement in major depression , 2005, Neuroreport.

[19]  James R. MacFall,et al.  The COMT Val158Met polymorphism and temporal lobe morphometry in healthy adults , 2007, Psychiatry Research: Neuroimaging.

[20]  Walter Heindel,et al.  Emotion specific modulation of automatic amygdala responses by 5-HTTLPR genotype , 2010, NeuroImage.

[21]  M. Barrot,et al.  Selective Loss of Brain-Derived Neurotrophic Factor in the Dentate Gyrus Attenuates Antidepressant Efficacy , 2008, Biological Psychiatry.

[22]  M. Danhof,et al.  The missing link between clinical endpoints and drug targets in depression. , 2010, Trends in pharmacological sciences.

[23]  Ahmad R. Hariri,et al.  Cognitive impact of genetic variation of the serotonin transporter in primates is associated with differences in brain morphology rather than serotonin neurotransmission , 2009, Molecular Psychiatry.

[24]  H. Möller,et al.  Depression-related variation in brain morphology over 3 years: effects of stress? , 2008, Archives of general psychiatry.

[25]  M. Trivedi,et al.  Variation in Catechol-O-Methyltransferase Is Associated with Duloxetine Response in a Clinical Trial for Major Depressive Disorder , 2009, Biological Psychiatry.

[26]  Yinghui Hu,et al.  BDNF and the diseased nervous system: a delicate balance between adaptive and pathological processes of gene regulation , 2008, Journal of neurochemistry.

[27]  E. Smeraldi,et al.  Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine , 1998, Molecular Psychiatry.

[28]  S. Leucht,et al.  Serotonin transporter polymorphisms and side effects in antidepressant therapy--a pilot study. , 2006, Pharmacogenomics.

[29]  Andreas Meyer-Lindenberg,et al.  Neural connectivity as an intermediate phenotype: Brain networks under genetic control , 2009, Human brain mapping.

[30]  M. Lowe,et al.  Activity and Connectivity of Brain Mood Regulating Circuit in Depression: A Functional Magnetic Resonance Study , 2005, Biological Psychiatry.

[31]  K. Itoh,et al.  Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[32]  P Riederer,et al.  Allelic Variation of Human Serotonin Transporter Gene Expression , 1996, Journal of neurochemistry.

[33]  S. Houle,et al.  Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. , 2001, The American journal of psychiatry.

[34]  Rebecca Elliott,et al.  The Effect of Citalopram Pretreatment on Neuronal Responses to Neuropsychological Tasks in Normal Volunteers: An fMRI Study , 2005, Neuropsychopharmacology.

[35]  N. Ozaki,et al.  The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine , 2007, Journal of psychopharmacology.

[36]  H. Smeets,et al.  Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors , 2007, International clinical psychopharmacology.

[37]  Leanne M Williams,et al.  COMT Val108/158Met polymorphism effects on emotional brain function and negativity bias , 2010, NeuroImage.

[38]  J. John Mann,et al.  Effect of BDNF val66met polymorphism on age-related amygdala volume changes in healthy subjects , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[39]  H. Manji,et al.  New insights into BDNF function in depression and anxiety , 2007, Nature Neuroscience.

[40]  P. Zwanzger,et al.  Serotonin-2A-receptor and -transporter polymorphisms: Lack of association in patients with major depression , 2001, European Neuropsychopharmacology.

[41]  M. Fava,et al.  Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment , 2003, Biological Psychiatry.

[42]  Stephan Ripke,et al.  A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. , 2009, Archives of general psychiatry.

[43]  A. Meyer-Lindenberg,et al.  5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression , 2005, Nature Neuroscience.

[44]  Dennis S. Charney,et al.  Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects , 2005, Biological Psychiatry.

[45]  R. Elliott,et al.  Neuronal effects of acute citalopram detected by pharmacoMRI , 2005, Psychopharmacology.

[46]  D Robinson,et al.  Brain-derived neurotrophic factor Val66met polymorphism and volume of the hippocampal formation , 2005, Molecular Psychiatry.

[47]  T. Kinoshita,et al.  Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism , 2005, International clinical psychopharmacology.

[48]  M. Essig,et al.  Hippocampal volume in first episode and recurrent depression , 2009, Psychiatry Research: Neuroimaging.

[49]  Francis J McMahon,et al.  Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. , 2007, Archives of general psychiatry.

[50]  Cristina Cusin,et al.  Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[51]  H. Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder , 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[52]  E. Smeraldi,et al.  Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. , 2000, Journal of clinical psychopharmacology.

[53]  Enrico Simonotto,et al.  The effects of escitalopram on working memory and brain activity in healthy adults during performance of the n-back task , 2006, Psychopharmacology.

[54]  Lourdes Fañanás,et al.  5-HTTLPR Polymorphism of the Serotonin Transporter Gene Predicts Non-Remission in Major Depression Patients Treated With Citalopram in a 12-Weeks Follow Up Study , 2003, Journal of clinical psychopharmacology.

[55]  Se-Won Lim,et al.  Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder , 2006, Brain Research.

[56]  G. Kranz,et al.  Reward and the serotonergic system , 2010, Neuroscience.

[57]  S. Cichon,et al.  Neural Mechanisms of a Genome-Wide Supported Psychosis Variant , 2009, Science.

[58]  J. Duncan,et al.  Effects of the Brain-Derived Neurotrophic Growth Factor Val66Met Variation on Hippocampus Morphology in Bipolar Disorder , 2009, Neuropsychopharmacology.

[59]  A. Schatzberg,et al.  Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. , 2004, Archives of general psychiatry.

[60]  Kunihiko Ito,et al.  No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment , 2002, European Neuropsychopharmacology.

[61]  Christian Montag,et al.  The BDNF Val66Met polymorphism affects amygdala activity in response to emotional stimuli: Evidence from a genetic imaging study , 2008, NeuroImage.

[62]  Justin S. Feinstein,et al.  Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. , 2005, Archives of general psychiatry.

[63]  E. Smeraldi,et al.  The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting , 2009, Psychopharmacology.

[64]  Jun Yu Li,et al.  Initial conditions of serotonin transporter kinetics and genotype: influence on ssri treatment trial outcome , 2002, Biological Psychiatry.

[65]  P. Nelemans,et al.  Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review , 2004, Molecular Psychiatry.

[66]  A. Caspi,et al.  Influence of Life Stress on Depression: Moderation by a Polymorphism in the 5-HTT Gene , 2003, Science.

[67]  F. Gianfagna,et al.  Meta-Analysis of the Brain-Derived Neurotrophic Factor Gene (BDNF) Val66Met Polymorphism in Anxiety Disorders and Anxiety-Related Personality Traits , 2008, Neuropsychobiology.

[68]  B. Kolachana,et al.  Variation in dopamine genes influences responsivity of the human reward system , 2009, Proceedings of the National Academy of Sciences.

[69]  Anastasia Konsta,et al.  Cingulate Neurobiology and Disease, B.A. Vogt (Ed.). Oxford University Press Inc., New York (2009), ISBN: 978-0-19-856696-0 , 2012 .

[70]  Byung-Joo Ham,et al.  Monoamine oxidase A–uVNTR genotype affects limbic brain activity in response to affective facial stimuli , 2008, Neuroreport.

[71]  C. Clary,et al.  The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder , 2004, Psychopharmacology.

[72]  Ariel Graff-Guerrero,et al.  Frontal and limbic metabolic differences in subjects selected according to genetic variation of the SLC6A4 gene polymorphism , 2005, NeuroImage.

[73]  Lukas Scheef,et al.  No association of the Val66Met polymorphism of the brain-derived neurotrophic factor with hippocampal volume in major depression , 2009, Psychiatric genetics.

[74]  T. Kinoshita,et al.  Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients , 2006, Neuropsychobiology.

[75]  M. Egan,et al.  Serotonin Transporter Genetic Variation and the Response of the Human Amygdala , 2002, Science.

[76]  Petti T. Pang,et al.  The yin and yang of neurotrophin action , 2005, Nature Reviews Neuroscience.

[77]  M. Raichle,et al.  Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism , 2002, European Neuropsychopharmacology.

[78]  W. Drevets,et al.  Imaging phenotypes of major depressive disorder: genetic correlates , 2009, Neuroscience.

[79]  Mark Lau,et al.  Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. , 2004, Archives of general psychiatry.

[80]  Joseph E LeDoux,et al.  Acute Selective Serotonin Reuptake Inhibitors Increase Conditioned Fear Expression: Blockade With a 5-HT2C Receptor Antagonist , 2007, Biological Psychiatry.

[81]  P. Bandettini,et al.  What's New in Neuroimaging Methods? , 2009, Annals of the New York Academy of Sciences.

[82]  Antonio Cerasa,et al.  MAO A VNTR polymorphism and variation in human morphology: a VBM study , 2008, Neuroreport.

[83]  A. Serretti,et al.  Effect of 5‐HT1A gene polymorphisms on antidepressant response in major depressive disorder , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[84]  M E Phelps,et al.  Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. , 2001, Archives of general psychiatry.

[85]  Bruce S. McEwen,et al.  Neurobiological and Clinical Effects of the Antidepressant Tianeptine , 2008, CNS drugs.

[86]  Ge Zhang,et al.  From Human Genetics and Genomics to Pharmacogenetics and Pharmacogenomics: Past Lessons, Future Directions , 2008 .

[87]  P. Cowen,et al.  Diminished Neural Processing of Aversive and Rewarding Stimuli During Selective Serotonin Reuptake Inhibitor Treatment , 2010, Biological Psychiatry.

[88]  M. Raichle,et al.  Subgenual prefrontal cortex abnormalities in mood disorders , 1997, Nature.

[89]  J. Mazziotta,et al.  Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression , 2005, Molecular Psychiatry.

[90]  Thomas E. Nichols,et al.  Impact of complex genetic variation in COMT on human brain function , 2006, Molecular Psychiatry.

[91]  Antonio Cerasa,et al.  Impact of catechol-O-methyltransferase Val108/158 Met genotype on hippocampal and prefrontal gray matter volume , 2008, Neuroreport.

[92]  John A. Detre,et al.  Genetic Variation in Serotonin Transporter Alters Resting Brain Function in Healthy Individuals , 2007, Biological Psychiatry.

[93]  Terry L. Jernigan,et al.  Seasonal Changes in Brain Serotonin Transporter Binding in Short Serotonin Transporter Linked Polymorphic Region-Allele Carriers but Not in Long-Allele Homozygotes , 2010, Biological Psychiatry.

[94]  John Suckling,et al.  A Longitudinal Functional Magnetic Resonance Imaging Study of Verbal Working Memory in Depression After Antidepressant Therapy , 2007, Biological Psychiatry.

[95]  T. Tencomnao,et al.  Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[96]  S. Tsai,et al.  Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder , 2006, The Pharmacogenomics Journal.

[97]  Vincent A Magnotta,et al.  Hippocampal volume and 2-year outcome in depression. , 2008, The British journal of psychiatry : the journal of mental science.

[98]  K. Lesch,et al.  Long story short: the serotonin transporter in emotion regulation and social cognition , 2007, Nature Neuroscience.

[99]  Marc Laruelle,et al.  Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [11C] DASB binding in the living human brain , 2010, NeuroImage.

[100]  I. Gottesman,et al.  The endophenotype concept in psychiatry: etymology and strategic intentions. , 2003, The American journal of psychiatry.

[101]  M. Egan,et al.  The BDNF val66met Polymorphism Affects Activity-Dependent Secretion of BDNF and Human Memory and Hippocampal Function , 2003, Cell.

[102]  Eliza Congdon,et al.  Additive effects of serotonin transporter and tryptophan hydroxylase-2 gene variation on neural correlates of affective processing , 2008, Biological Psychology.

[103]  N. Logothetis What we can do and what we cannot do with fMRI , 2008, Nature.

[104]  Michael F Egan,et al.  A susceptibility gene for affective disorders and the response of the human amygdala. , 2005, Archives of general psychiatry.

[105]  M C O'Donovan,et al.  The catechol-O-methyl transferase (COMT) gene as a candidate for psychiatric phenotypes: evidence and lessons , 2006, Molecular Psychiatry.

[106]  John Suckling,et al.  Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. , 2004, Archives of general psychiatry.

[107]  D. Blackwood,et al.  Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy , 2009, The Pharmacogenomics Journal.

[108]  René Hen,et al.  Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult , 2002, Nature.

[109]  Kazuhiko Yanai,et al.  Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention , 2009, NeuroImage.

[110]  C. Nemeroff,et al.  Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. , 2010, The American journal of psychiatry.

[111]  S. Rauch,et al.  Neurobiology of emotion perception I: the neural basis of normal emotion perception , 2003, Biological Psychiatry.

[112]  Giuseppe Blasi,et al.  Neural mechanisms of genetic risk for impulsivity and violence in humans. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[113]  C. Gross,et al.  Postnatal handling reverses social anxiety in serotonin receptor 1A knockout mice , 2010, Genes, brain, and behavior.

[114]  Andreas Heinz,et al.  Catechol-O-Methyltransferase val158met Genotype Affects Processing of Emotional Stimuli in the Amygdala and Prefrontal Cortex , 2005, The Journal of Neuroscience.

[115]  Timothy Edward John Behrens,et al.  Contrasting roles for cingulate and orbitofrontal cortex in decisions and social behaviour , 2007, Trends in Cognitive Sciences.

[116]  G. Jenkins,et al.  A Genomewide Association Study of Citalopram Response in Major Depressive Disorder , 2010, Biological Psychiatry.

[117]  C. Montag,et al.  The BDNF Val66Met polymorphism impacts parahippocampal and amygdala volume in healthy humans: incremental support for a genetic risk factor for depression , 2009, Psychological Medicine.

[118]  Abraham Z. Snyder,et al.  A default mode of brain function: A brief history of an evolving idea , 2007, NeuroImage.

[119]  Michael J. Anderle,et al.  The neural substrates of affective processing in depressed patients treated with venlafaxine. , 2003, The American journal of psychiatry.

[120]  Eric J. Nestler,et al.  The molecular neurobiology of depression , 2008, Nature.

[121]  John Suckling,et al.  Neural responses to happy facial expressions in major depression following antidepressant treatment. , 2007, The American journal of psychiatry.

[122]  Francesco Fera,et al.  Genetically dependent modulation of serotonergic inactivation in the human prefrontal cortex , 2008, NeuroImage.

[123]  P. Cowen,et al.  Normalization of enhanced fear recognition by acute SSRI treatment in subjects with a previous history of depression. , 2004, The American journal of psychiatry.

[124]  K. Lesch,et al.  CRSN Symposium : Focus on Depression , Part I Symposium du CRSN : le point sur la dépression , première partie Gene – environment interaction and the genetics of depression , 2004 .

[125]  Gerty J. L. M. Lensvelt-Mulders,et al.  Brain volume abnormalities in major depressive disorder: A meta‐analysis of magnetic resonance imaging studies , 2009, Human brain mapping.

[126]  M. Fukuda,et al.  HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic/paralimbic regions , 2007, Psychiatry Research: Neuroimaging.

[127]  A. Heinz,et al.  Midbrain serotonin transporter binding potential measured with [11C]DASB is affected by serotonin transporter genotype , 2007, Journal of Neural Transmission.

[128]  C. Siao,et al.  Genetic Variant BDNF (Val66Met) Polymorphism Alters Anxiety-Related Behavior , 2006, Science.

[129]  R. Duman,et al.  A Neurotrophic Model for Stress-Related Mood Disorders , 2006, Biological Psychiatry.

[130]  M. Rietschel,et al.  Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter. , 2000, Pharmacopsychiatry.

[131]  F. Holsboer How can we realize the promise of personalized antidepressant medicines? , 2008, Nature Reviews Neuroscience.

[132]  Yong He,et al.  Functional and Structural Connectivity Between the Perigenual Anterior Cingulate and Amygdala in Bipolar Disorder , 2009, Biological Psychiatry.

[133]  S. Kapur,et al.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use? , 2008, Schizophrenia bulletin.

[134]  Yoshiro Okubo,et al.  No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET , 2003, Synapse.

[135]  P. Muglia,et al.  Genome-wide association study of recurrent major depressive disorder in two European case–control cohorts , 2010, Molecular Psychiatry.

[136]  Hans-Jürgen Möller,et al.  Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects , 2003, Biological Psychiatry.

[137]  M. Furey,et al.  Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression , 2008, Brain Structure and Function.

[138]  E. Castrén,et al.  Activation of the TrkB Neurotrophin Receptor Is Induced by Antidepressant Drugs and Is Required for Antidepressant-Induced Behavioral Effects , 2003, The Journal of Neuroscience.

[139]  Eric Stice,et al.  Frontal-Limbic White Matter Pathway Associations with the Serotonin Transporter Gene Promoter Region (5-HTTLPR) Polymorphism , 2009, The Journal of Neuroscience.

[140]  Randy L. Gollub,et al.  The COMT Val108/158Met polymorphism and medial temporal lobe volumetry in patients with schizophrenia and healthy adults , 2009, NeuroImage.

[141]  Nicholas D. Walsh,et al.  Functional Coupling of the Amygdala in Depressed Patients Treated with Antidepressant Medication , 2008, Neuropsychopharmacology.

[142]  J Kirchheiner,et al.  CYP2D6 in the brain: genotype effects on resting brain perfusion , 2011, Molecular Psychiatry.

[143]  Steven P. Hamilton,et al.  Sequence Analysis of the Serotonin Transporter and Associations with Antidepressant Response , 2005, Biological Psychiatry.

[144]  Ahmad R. Hariri,et al.  Genetic Variation in Maoa Modulates Ventromedial Prefrontal Circuitry Mediating Individual Differences in Human Personality , 2022 .

[145]  A. Meyer-Lindenberg,et al.  The Brain-derived Neurotrophic Factor Val66met Polymorphism and Variation in Human Cortical Morphology , 2022 .

[146]  E. Nestler,et al.  Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action , 2006, Nature Neuroscience.

[147]  R. Elliott,et al.  Assessing human 5-HT function in vivo with pharmacoMRI , 2008, Neuropharmacology.

[148]  R. Kahn,et al.  Effects of brain‐derived neurotrophic factor Val66Met polymorphism on hippocampal volume change in schizophrenia , 2010, Hippocampus.

[149]  N. Ozaki,et al.  Influence of the tyrosine hydroxylase val81met polymorphism and catechol‐O‐methyltransferase val158met polymorphism on the antidepressant effect of milnacipran , 2008, Human psychopharmacology.

[150]  K. Lesch,et al.  Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region , 1996, Science.

[151]  D. Bylund,et al.  Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. , 2008, Pharmacology & therapeutics.

[152]  D. Kumaran,et al.  A Genetically Mediated Bias in Decision Making Driven by Failure of Amygdala Control , 2009, The Journal of Neuroscience.

[153]  Hidehiro Iida,et al.  The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia. , 2006, Brain : a journal of neurology.

[154]  S. Menzel,et al.  Genetic and Molecular Analyses of Complex Metabolic Disorders: Genetic Linkage , 2002, Annals of the New York Academy of Sciences.

[155]  H. Flor,et al.  Gene–gene effects on central processing of aversive stimuli , 2007, Molecular Psychiatry.

[156]  Joseph E. LeDoux,et al.  The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine , 2004, Biological Psychiatry.

[157]  I. Lucki,et al.  5-HT1A receptor function in major depressive disorder , 2009, Progress in Neurobiology.

[158]  L. Fañanás,et al.  Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. , 2006, Journal of affective disorders.

[159]  J. Knowles,et al.  Investigation of serotonin-related genes in antidepressant response , 2004, Molecular Psychiatry.

[160]  Remco J. Renken,et al.  Neuroticism modulates amygdala—prefrontal connectivity in response to negative emotional facial expressions , 2010, NeuroImage.

[161]  Marcello Cadioli,et al.  Neural and genetic correlates of antidepressant response to sleep deprivation: a functional magnetic resonance imaging study of moral valence decision in bipolar depression. , 2007, Archives of general psychiatry.

[162]  A. Meyer-Lindenberg,et al.  Intermediate phenotypes and genetic mechanisms of psychiatric disorders , 2006, Nature Reviews Neuroscience.

[163]  M. Daly,et al.  Genetic Mapping in Human Disease , 2008, Science.

[164]  N. Kinukawa,et al.  Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. , 2008, The international journal of neuropsychopharmacology.

[165]  Paul J. Harrison,et al.  Catechol-o-Methyltransferase, Cognition, and Psychosis: Val158Met and Beyond , 2006, Biological Psychiatry.

[166]  R. Hashimoto,et al.  Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder. , 2006, Psychiatric genetics.

[167]  P. Cowen,et al.  A single dose of citalopram increases fear recognition in healthy subjects , 2007, Journal of psychopharmacology.

[168]  P. Joyce,et al.  Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. , 2003, The international journal of neuropsychopharmacology.

[169]  M. Wong,et al.  Research and treatment approaches to depression , 2001, Nature Reviews Neuroscience.

[170]  R. Hen,et al.  Early-Life Blockade of the 5-HT Transporter Alters Emotional Behavior in Adult Mice , 2004, Science.

[171]  G. Goodwin,et al.  Polymorphism in serotonin transporter gene associated with susceptibility to major depression , 1996, The Lancet.

[172]  W. Millard,et al.  Assessment of Human Serotonin 1A Receptor Polymorphisms and SSRI Responsiveness , 2012, Molecular Diagnosis & Therapy.

[173]  P. Albert,et al.  Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. , 2004, The international journal of neuropsychopharmacology.

[174]  Michele T. Diaz,et al.  Effect of bupropion extended release on negative emotion processing in major depressive disorder: a pilot functional magnetic resonance imaging study. , 2007, The Journal of clinical psychiatry.

[175]  K. Ressler,et al.  Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic , 2007, Nature Neuroscience.

[176]  Daniel R. Weinberger,et al.  Variation of Human Amygdala Response During Threatening Stimuli as a Function of 5′HTTLPR Genotype and Personality Style , 2005, Biological Psychiatry.

[177]  V. Arango,et al.  A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. , 2000, Archives of general psychiatry.

[178]  Lucy R Forrest,et al.  Fluoxetine (Prozac) Binding to Serotonin Transporter Is Modulated by Chloride and Conformational Changes , 2009, The Journal of Neuroscience.

[179]  Walter Heindel,et al.  5-HTTLPR Biases Amygdala Activity in Response to Masked Facial Expressions in Major Depression , 2008, Neuropsychopharmacology.

[180]  A. Serretti,et al.  The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. , 2004, The international journal of neuropsychopharmacology.

[181]  D. Nutt,et al.  Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression , 2009, European Neuropsychopharmacology.

[182]  V. Arolt,et al.  Serotonin receptor 1A −1019C/G variant: Impact on antidepressant pharmacoresponse in melancholic depression? , 2008, Neuroscience Letters.

[183]  Amit Anand,et al.  Brain Imaging Studies in Mood and Anxiety Disorders , 2003, Annals of the New York Academy of Sciences.

[184]  Tilo Kircher,et al.  COMT genotype and its role on hippocampal–prefrontal regions in declarative memory , 2010, NeuroImage.

[185]  P. Gaspar,et al.  The developmental role of serotonin: news from mouse molecular genetics , 2003, Nature Reviews Neuroscience.

[186]  M. Wong,et al.  Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. , 2009, Archives of general psychiatry.

[187]  D. Schaid,et al.  SLC6A4 variation and citalopram response , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[188]  J. Geddes,et al.  Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis , 2009, The Lancet.

[189]  Peter N. C. Mohr,et al.  Genetic variation in dopaminergic neuromodulation influences the ability to rapidly and flexibly adapt decisions , 2009, Proceedings of the National Academy of Sciences.

[190]  S. Ryu,et al.  Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment , 2004, Psychiatric genetics.

[191]  P. Gaspar,et al.  New perspectives on the neurodevelopmental effects of SSRIs. , 2010, Trends in pharmacological sciences.

[192]  Helen S Mayberg,et al.  Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. , 2007, The American journal of psychiatry.

[193]  Pienie Zwitserlood,et al.  Reduced amygdala-prefrontal coupling in major depression: association with MAOA genotype and illness severity. , 2009, The international journal of neuropsychopharmacology.

[194]  Eliza Congdon,et al.  Neural correlates of epigenesis , 2006, Proceedings of the National Academy of Sciences.

[195]  Glenda M. MacQueen,et al.  Posterior Hippocampal Volumes Are Associated with Remission Rates in Patients with Major Depressive Disorder , 2008, Biological Psychiatry.

[196]  D. Lawlor,et al.  Genetic association study of BDNF in depression: Finding from two cohort studies and a meta‐analysis , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[197]  M. Rietschel,et al.  Moderation of antidepressant response by the serotonin transporter gene , 2009, British Journal of Psychiatry.

[198]  J. McKenzie,et al.  Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. , 2007, The Cochrane database of systematic reviews.

[199]  Yang Wang,et al.  Reciprocal effects of antidepressant treatment on activity and connectivity of the mood regulating circuit: an FMRI study. , 2007, The Journal of neuropsychiatry and clinical neurosciences.

[200]  Harald H. Sitte,et al.  Imaging genetics of mood disorders , 2010, NeuroImage.

[201]  S Cichon,et al.  Effects of a genome-wide supported psychosis risk variant on neural activation during a theory-of-mind task , 2011, Molecular Psychiatry.

[202]  H. Breiter,et al.  BDNF, relative preference, and reward circuitry responses to emotional communication , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[203]  Monique Ernst,et al.  fMRI predictors of treatment outcome in pediatric anxiety disorders , 2007, Psychopharmacology.

[204]  B. Lebowitz,et al.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. , 2006, The American journal of psychiatry.

[205]  B. Franke,et al.  Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity , 2010, Molecular Psychiatry.

[206]  B. Ravnkilde,et al.  Hippocampal volume and depression: a meta-analysis of MRI studies. , 2004, The American journal of psychiatry.

[207]  M. Skolnick,et al.  Evidence for HTR1A and LHPP as interacting genetic risk factors in major depression , 2009, Molecular Psychiatry.

[208]  Sylvain Houle,et al.  Novel 5-HTTLPR Allele Associates with Higher Serotonin Transporter Binding in Putamen: A [11C] DASB Positron Emission Tomography Study , 2007, Biological Psychiatry.

[209]  V. Arolt,et al.  Human Fear Conditioning and Extinction in Neuroimaging: A Systematic Review , 2009, PloS one.

[210]  B. V. Zwieten-Boot,et al.  A regulatory Apologia — A review of placebo-controlled studies in regulatory submissions of new-generation antidepressants , 2008, European Neuropsychopharmacology.

[211]  Christian Büchel,et al.  Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter , 2005, Nature Neuroscience.

[212]  David Goldman,et al.  Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. , 2006, American journal of human genetics.

[213]  S. Nanko,et al.  Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder , 1997, Molecular Psychiatry.

[214]  A. Serretti,et al.  Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder , 2010, Molecular Psychiatry.

[215]  A. Janssens,et al.  Meta-analyses of genetic studies on major depressive disorder , 2008, Molecular Psychiatry.

[216]  David Goldman,et al.  Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. , 2006, The American journal of psychiatry.

[217]  M. McInnis,et al.  Psychiatric genetics: progress amid controversy , 2008, Nature Reviews Genetics.

[218]  Deborah A Yurgelun-Todd,et al.  Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study , 2000, Biological Psychiatry.

[219]  Joseph H. Callicott,et al.  Impact of interacting functional variants in COMT on regional gray matter volume in human brain , 2009, NeuroImage.

[220]  A. Meyer-Lindenberg,et al.  Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression , 2008, Molecular Psychiatry.

[221]  B. Carroll,et al.  Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. , 2006, JAMA.

[222]  Russell A. Poldrack,et al.  Guidelines for reporting an fMRI study , 2008, NeuroImage.

[223]  P. Jerabek,et al.  Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response , 2000, Biological Psychiatry.

[224]  Nikos K Logothetis,et al.  The ins and outs of fMRI signals , 2007, Nature Neuroscience.

[225]  Carol Dobson-Stone,et al.  Disturbances in selective information processing associated with the BDNF Val66Met polymorphism: Evidence from cognition, the P300 and fronto-hippocampal systems , 2009, Biological Psychology.

[226]  Dan J Stein,et al.  Psychobiology of Mindfulness , 2008, CNS Spectrums.

[227]  Gloria Olivieri,et al.  ‘Negativity bias’ in risk for depression and anxiety: Brain–body fear circuitry correlates, 5-HTT-LPR and early life stress , 2009, NeuroImage.

[228]  Andreas Meyer-Lindenberg,et al.  Catechol O-methyltransferase val158met genotype and neural mechanisms related to affective arousal and regulation. , 2006, Archives of general psychiatry.

[229]  J. Price,et al.  Glial reduction in the subgenual prefrontal cortex in mood disorders. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[230]  J. Potash,et al.  Novel loci for major depression identified by genome-wide association study of STAR*D and meta-analysis of three studies , 2009, Molecular Psychiatry.

[231]  V. Arolt,et al.  Association of the COMT val158met Variant with Antidepressant Treatment Response in Major Depression , 2008, Neuropsychopharmacology.

[232]  A. Meyer-Lindenberg,et al.  Neural substrates of pleiotropic action of genetic variation in COMT: a meta-analysis , 2010, Molecular Psychiatry.

[233]  C. Cusin,et al.  Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. , 2002, The international journal of neuropsychopharmacology.

[234]  M. Wong,et al.  Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[235]  A. Simmons,et al.  Escitalopram effects on insula and amygdala BOLD activation during emotional processing , 2008, Psychopharmacology.

[236]  J. Ashburner,et al.  Prognostic and Diagnostic Potential of the Structural Neuroanatomy of Depression , 2009, PloS one.

[237]  Margot Albus,et al.  Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression , 2004, Biological Psychiatry.

[238]  M. Egan,et al.  Brain-Derived Neurotrophic Factor val66met Polymorphism Affects Human Memory-Related Hippocampal Activity and Predicts Memory Performance , 2003, The Journal of Neuroscience.

[239]  S. Rauch,et al.  Neurobiology of emotion perception II: implications for major psychiatric disorders , 2003, Biological Psychiatry.

[240]  D. A. Lewis,et al.  SERT-ainly involved in depression, but when? , 2006, The American journal of psychiatry.

[241]  J. Hirschhorn,et al.  A comprehensive review of genetic association studies , 2002, Genetics in Medicine.

[242]  K. Ressler,et al.  Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories , 2007, Molecular Psychiatry.

[243]  S. Tsai,et al.  Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders , 2006, European Neuropsychopharmacology.

[244]  H. Möller,et al.  Reduced gray matter brain volumes are associated with variants of the serotonin transporter gene in major depression , 2008, Molecular Psychiatry.

[245]  E. Castrén,et al.  Is mood chemistry? , 2005, Nature Reviews Neuroscience.

[246]  Gustavo Turecki,et al.  Impaired Repression at a 5-Hydroxytryptamine 1A Receptor Gene Polymorphism Associated with Major Depression and Suicide , 2003, The Journal of Neuroscience.

[247]  K. Itoh,et al.  Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[248]  Andrew J. Saykin,et al.  Voxelwise genome-wide association study (vGWAS) , 2010, NeuroImage.

[249]  B. Carroll,et al.  Serotonin transporter gene polymorphism and antidepressant response , 2000, Neuroreport.

[250]  Morten L. Kringelbach,et al.  The personality trait openness is related to cerebral 5-HTT levels , 2009, NeuroImage.

[251]  M. Gratacós,et al.  A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders , 2008, The Pharmacogenomics Journal.

[252]  Clare E. Mackay,et al.  A Systematic Review of Diffusion Tensor Imaging Studies in Affective Disorders , 2009, Biological Psychiatry.

[253]  M. Goodell,et al.  Genome-wide association study of recurrent early-onset major depressive disorder , 2010, Molecular Psychiatry.

[254]  S. Tsai,et al.  Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders , 2002, Molecular Psychiatry.

[255]  A. Kersting,et al.  Serotonergic genes modulate amygdala activity in major depression , 2007, Genes, brain, and behavior.

[256]  Blair T. Johnson,et al.  Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration , 2008, PLoS medicine.

[257]  Patrick M Fisher,et al.  Acute 5-HT Reuptake Blockade Potentiates Human Amygdala Reactivity , 2008, Neuropsychopharmacology.

[258]  D. Ye,et al.  Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder , 2010, European Neuropsychopharmacology.

[259]  John P Hatch,et al.  Neuronal Correlates of Brain-derived Neurotrophic Factor Val66Met Polymorphism and Morphometric Abnormalities in Bipolar Disorder , 2009, Neuropsychopharmacology.

[260]  E. Rolls,et al.  The orbitofrontal cortex and beyond: From affect to decision-making , 2008, Progress in Neurobiology.

[261]  Andreas Meyer-Lindenberg,et al.  False positives in imaging genetics , 2008, NeuroImage.

[262]  Yung-Tian A Gau,et al.  Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. , 2009, Journal of affective disorders.

[263]  D. Hamer,et al.  A functional polymorphism in the monoamine oxidase A gene promoter , 1998, Human Genetics.

[264]  E. Pomarol-Clotet,et al.  COMT Val158Met polymorphism in relation to activation and de-activation in the prefrontal cortex: A study in patients with schizophrenia and healthy subjects , 2010, NeuroImage.

[265]  S. Tsai,et al.  Association study of a brain‐derived neurotrophic‐factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[266]  Margit Burmeister,et al.  BDNF Val66Met Allele Is Associated with Reduced Hippocampal Volume in Healthy Subjects , 2006, Biological Psychiatry.

[267]  R Todd Constable,et al.  Role of Variation in the Serotonin Transporter Protein Gene (SLC6A4) in Trait Disturbances in the Ventral Anterior Cingulate in Bipolar Disorder , 2009, Neuropsychopharmacology.

[268]  Hans-Jürgen Möller,et al.  Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. , 2008, Journal of psychiatry & neuroscience : JPN.

[269]  A. Hariri,et al.  Neuroimaging studies of serotonin gene polymorphisms: Exploring the interplay of genes, brain, and behavior , 2006, Cognitive, affective & behavioral neuroscience.

[270]  B. McEwen,et al.  Plasticity of the Hippocampus: Adaptation to Chronic Stress and Allostatic Load , 2001, Annals of the New York Academy of Sciences.

[271]  P. Whalen,et al.  The Structural Integrity of an Amygdala–Prefrontal Pathway Predicts Trait Anxiety , 2009, The Journal of Neuroscience.

[272]  T. Werge,et al.  Antidepressive-drug-induced bodyweight gain is associated with polymorphisms in genes coding for COMT and TPH1 , 2009, International clinical psychopharmacology.

[273]  S. Kasper,et al.  The role of pharmacogenetics in the treatment of depression and anxiety disorders , 2009, International clinical psychopharmacology.

[274]  B. Ham,et al.  Serotonergic genes and amygdala activity in response to negative affective facial stimuli in Korean women , 2008, Genes, brain, and behavior.

[275]  Nick C. Fox,et al.  Ten simple rules for reporting voxel-based morphometry studies , 2008, NeuroImage.

[276]  C. Cusin,et al.  Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-httlpr in delusional and nondelusional depression , 2001, Biological Psychiatry.

[277]  D. Blackwood,et al.  A splice site polymorphism in the G-protein &bgr; subunit influences antidepressant efficacy in depression , 2007, Pharmacogenetics and genomics.

[278]  Hans-Jürgen Möller,et al.  Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. , 2007, Archives of general psychiatry.

[279]  Siegfried Kasper,et al.  Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: A randomized cross-over study , 2010, NeuroImage.

[280]  D. Kupfer,et al.  Allelic Variation in the Serotonin Transporter Promoter Affects Onset of Paroxetine Treatment Response in Late-Life Depression , 2000, Neuropsychopharmacology.

[281]  Patrick M Fisher,et al.  Effects of HTR1A C(-1019)G on amygdala reactivity and trait anxiety. , 2009, Archives of general psychiatry.

[282]  Guy M. Goodwin,et al.  Antidepressant Drug Treatment Modifies the Neural Processing of Nonconscious Threat Cues , 2006, Biological Psychiatry.

[283]  Martha J. Farah,et al.  COMT genotype influences prefrontal response to emotional distraction , 2006, Cognitive, affective & behavioral neuroscience.

[284]  S. Alborzian,et al.  Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine , 1999, Psychiatry Research: Neuroimaging.

[285]  M. Munafo,et al.  The endophenotype concept in psychiatric genetics , 2006, Psychological Medicine.

[286]  N. Božina,et al.  Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder , 2008, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[287]  Christian Büchel,et al.  5-HTT genotype effect on prefrontal–amygdala coupling differs between major depression and controls , 2009, Psychopharmacology.

[288]  P. Cowen,et al.  Increased Positive versus Negative Affective Perception and Memory in Healthy Volunteers following Selective Serotonin and Norepinephrine Reuptake Inhibition , 2022 .

[289]  S. Tsai,et al.  Association Study of a Monoamine Oxidase A Gene Promoter Polymorphism with Major Depressive Disorder and Antidepressant Response , 2005, Neuropsychopharmacology.

[290]  Karl J. Friston,et al.  Voxel-Based Morphometry—The Methods , 2000, NeuroImage.

[291]  A. Serretti,et al.  Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients , 2007, Molecular Psychiatry.

[292]  P. McGuffin,et al.  Linkage and associated studies of schizophrenia. , 2000, American journal of medical genetics.

[293]  R Todd Constable,et al.  Beyond affect: a role for genetic variation of the serotonin transporter in neural activation during a cognitive attention task. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[294]  E. Lander,et al.  Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease , 2003, Nature Genetics.

[295]  J. Sasse,et al.  A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment , 2007, The Pharmacogenomics Journal.

[296]  M. Ergun,et al.  Serotonin transporter gene polymorphisms and sertraline response in major depression patients. , 2008, Genetic testing.

[297]  F. McMahon Pioneering First Steps and Cautious Conclusions , 2010, Biological Psychiatry.

[298]  M. Mintun,et al.  Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study , 2001, Biological Psychiatry.

[299]  F. McMahon,et al.  Brain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response. , 2009, The international journal of neuropsychopharmacology.

[300]  D. Roden,et al.  The genetic basis of variability in drug responses , 2002, Nature Reviews Drug Discovery.

[301]  O. Taboureau,et al.  Location of the Antidepressant Binding Site in the Serotonin Transporter , 2009, Journal of Biological Chemistry.

[302]  E. Binder,et al.  Pharmacogenomics of antidepressant drugs. , 2009, Pharmacology & therapeutics.

[303]  R. Weinshilboum Inheritance and drug response. , 2003, The New England journal of medicine.

[304]  P. Fox,et al.  Cingulate function in depression: a potential predictor of treatment response , 1997, Neuroreport.

[305]  Takashi Asada,et al.  The Val66Met polymorphism of the brain-derived neurotrophic factor gene affects age-related brain morphology , 2006, Neuroscience Letters.

[306]  J. Hauser,et al.  [Association between polymorphisms of Val66Met in the BDNF gene and the response to escitalopram and nortriptyline treatment in the light of the neurodevelopmental hypothesis of depression]. , 2008, Psychiatria polska.

[307]  Sophia Frangou,et al.  The effects of gender and COMT Val158Met polymorphism on fearful facial affect recognition: a fMRI study. , 2009, The international journal of neuropsychopharmacology.

[308]  T. Lehtimäki,et al.  Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression , 2007, Journal of Neural Transmission.